Merck & Co., Inc. (MRK)
Listed on NYSE • Healthcare / Drug Manufacturers - General
Overview
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Explore More Data
Key Information
Symbol:
MRK
CEO:
Robert M. Davis
Exchange:
NYSE
CIK:
0000310158
Website:
https://www.merck.com
SEC Filings:
View SEC →
Stock Snapshot (Updated: Nov 05 03:59 PM EST)
Price
84.41
Change
0.55
Change %
0.66%
Open
84.03
Previous Close
83.86
High
85.38
Low
82.91
Volume
7,469,647
Market Cap
210,837,897,216
EV/EBITDA
9.18
Capital Structure (Updated: Nov 05 03:59 PM EST)
Shares Outstanding
2,497,783,211
FloatShares
2,493,836,714
Float Ratio
99.84%
Shares Short
26,700,419
Short Percent Of Float
The percent of float shares currently sold short. Reflects market sentiment and risk of a short squeeze.
1.19%
Short Ratio
Days needed to cover all short positions. Indicates short-selling pressure.
2 trading days
Held Percent Insiders
0.07%
Held Percent Institutions
80.86%
Calendar Events (Upcoming Earnings & Revenue Forecasts)
| Earnings | |
| Earnings Date | 2025-10-30 |
| Earnings Call | 2026-02-03 |
| Avg EPS Estimate | 2.036 |
| Low EPS Estimate | 2.03 |
| High EPS Estimate | 2.06 |
| Revenue | |
| Avg Revenue Forecast | 16,204,334,360 |
| Low Revenue Forecast | 16,103,000,000 |
| High Revenue Forecast | 16,310,500,000 |
MRK Liquidity Indicators Shows key metrics that reflect cash availability and short-term payment ability
| Field | Value | Description |
|---|---|---|
| Cash Holdings | $8,622,000,128 | Cash on hand, which directly shows a company's ability to meet short-term obligations. |
| Quick Ratio | 0 | The quick ratio, which excludes inventory, measures short-term solvency; a value above 1 is considered relatively safe. |
| Current Ratio | 0 | The current ratio, calculated as current assets divided by current liabilities; the higher the value, the better the liquidity. |
| Total Debt | $35,401,998,336 | Total liabilities, used together with cash and liquidity ratios to assess debt burden. |
MRK Profitability Indicators Shows key metrics that reflect overall earnings, margins, and core business profitability
| Field | Value | Description |
|---|---|---|
| EBITDA | $31,541,999,616 | EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization), which measures the profitability of core operations. |
| Operating Cash Flow | $0 | Operating cash flow, which reflects a company's cash-generating ability. |
| Free Cash Flow | $0 | Free cash flow, after deducting capital expenditures, which can be used for dividends or reinvestment. |
| Gross Margin | 78.02% | Gross margin; a higher value indicates stronger product profitability. |
| Operating Margin | 44.62% | Operating margin; slightly negative, indicating high operating costs. |
| Profit Margin | 29.63% | Net profit margin, which reflects overall profitability. |
MRK Leverage & Financial Health Indicators Shows key metrics that reflect debt levels, liquidity, and overall financial stability
| Field | Value | Description |
|---|---|---|
| Debt/Equity Ratio | 72.16% | Low leverage level, indicating the company has low debt pressure. |
| Total Debt | $35,401,998,336 | Used together with cash and EBITDA to assess debt-paying ability. |
MRK Growth Indicators Shows key financial metrics that reflect profitability, cash flow, and business expansion
| Field | Value | Description |
|---|---|---|
| Revenue Growth (YoY) | 3.70% | Rapid revenue growth, indicating fast business expansion. |
| Earnings Growth (YoY) | 86.80% | Significant EPS growth, indicating rapid improvement in profitability. |
Financial Data for MRK (Key ratios, margins, and cash flow)
| Field | Value | Description |
|---|---|---|
| Current Price | $84.39 | Latest stock trading price |
| Price Target (High) | $137 | Analyst highest expected price |
| Price Target (Low) | $82 | Analyst lowest expected price |
| Price Target (Average) | $101.54 | Average target price across analysts |
| Price Target (Median) | $99 | Median of target prices |
| Average Rating Score | 2.04 | Average analyst rating (1=Strong Buy, 5=Sell) |
| Consensus Recommendation | buy | Consensus rating |
| Analyst Coverage Count | 24 | Number of analysts providing estimates |
| Cash Holdings | $8,622,000,128 | Total cash held by the company |
| Cash per Share | $3.45 | Cash value per outstanding share |
| Total Debt | $35,401,998,336 | Company's total debt |
| Quick Ratio | 0 | Ability to cover short-term liabilities (excludes inventory) |
| Current Ratio | 0 | Overall short-term liquidity |
| Debt/Equity Ratio | 72.16% | Leverage ratio: Debt / Equity |
| EBITDA | $31,541,999,616 | Earnings before interest, taxes, depreciation & amortization |
| Total Revenue | $64,234,999,808 | Total company revenue |
| Revenue per Share | $25.589 | Total revenue divided by shares outstanding |
| Gross Profit | 78.02% | Revenue minus cost of goods sold |
| Return on Assets | 0.00% | Net income / Total assets |
| Return on Equity | 0.00% | Net income / Shareholder equity |
| Earnings Growth (YoY) | 86.80% | Year-over-year EPS growth |
| Revenue Growth (YoY) | 3.70% | Year-over-year revenue growth |
| Gross Margin | 78.02% | Gross profit / Total revenue |
| EBITDA Margin | 49.10% | EBITDA / Revenue |
| Operating Margin | 44.62% | Operating income / Revenue |
| Profit Margin | 29.63% | Net income / Revenue |
| Free Cash Flow | $0 | Cash left after capital expenditures |
| Operating Cash Flow | $0 | Cash from core business operations |
| Currency | USD | Reported in US dollars |
| Last Updated | 2025-11-05 | Data source from Yahoo |